Allan Shaw is a seasoned biopharma executive with over 30 years of experience, having served as Chief Financial Officer and Board Member for multiple public and private companies in the Life Sciences. He has raised more than $5 billion of Equity and Debt in the United States and International markets including four initial public offerings. Mr. Shaw has far-reaching expertise in funding drug development companies and executing on their respective business plans by bringing drugs and therapies successfully to market. In one case he led a company in scaling up from Twenty million dollars in revenue to over Seven Hundred and Fifty million dollars in revenue. He is involved with a diverse portfolio of healthcare companies in various stages of development as a Board Member, Consultant, and Investor.
Wayne Curtis “Curt” Weldon named Vice Chairman of Ellington Healthcare Asset Management and NSIP LLC. Congressman Weldon served 20 years in the United States House representing the Seventh Congressional District of Pennsylvania and represented the 6 mid-Atlantic States on the House Steering Committee. he served as the Vice Chairman of the Armed Services Committee, and Chairman of the Research & Development and Procurement Sub-Committees as well as Vice Chairman of the Homeland Security Committee. In these capacities Congressman Weldon was responsible for the oversight of tens of billions of research dollars allocated through dozens of the largest Department of Defense and Department of Energy agencies such as: DARPA, DTRA, MTEC, U.S. Army Medical Research and Material Command.
Robert Sackstein, M.D., Ph.D., named as the second Dean of the Herbert Wertheim College of Medicine at the Florida International University (FIU) and the Senior Vice-President of the FIU Academic Health Center. He is a world-renowned bone marrow transplant physician and biomedical researcher. He was born in Havana, Cuba, and immigrated to Miami, FL, where he attended Miami public schools. He received his undergraduate degree (in Biology) from Harvard College, Summa cum Laude, and his M.D. and Ph.D. (in Immunology) degrees from Harvard Medical School, where he also received the James Tolbert Shipley Prize for outstanding research. He then completed internal medicine training and fellowships in immunology and hematology at the University of Miami, and received the Young Investigator Award for Excellence in the Field of Hematology from the International Society for Experimental Hematology. Dr. Sackstein is an authority in stem cell-based “regenerative” medicine, immunology, and glycobiology, and his research efforts have defined how cells in blood flow migrate to target tissues. In particular, he is widely recognized for developing a platform technology known as “glycosyltransferase-programmed stereosubstitution” (GPS) for steering the trafficking of intravenously administered cells directly to sites of tissue injury or cancer, a necessary first step in achieving the promise of regenerative therapeutics and of adoptive cell immunotherapy. Before coming to FIU, he served as a Bone Marrow Transplant Physician at the Massachusetts General Hospital, the Brigham and Women’s Hospital, and the Dana-Farber Cancer Institute, and held dual-appointment Professorships (in the fields of Medicine and Dermatology) at the Harvard Medical School. In addition, he served as the Director of the Program of Excellence in Glycosciences at Harvard Medical School, and the Co-director of the Harvard Center for Glycoscience. In addition to his appointments at FIU, Dr. Sackstein is an Emeritus Professor at Harvard Medical School, he is on the International Scientific Advisory Board of the Wallenberg Center for Regenerative Medicine (University of Lund, Sweden), is the Chairperson of the Advisory Board for the Spanish National Network for Regenerative Medicine, and is a member of the Scientific Advisory Boards of the Jose Carreras Institute and the Bellvitge Institute for Biomedical Research (IDIBELL), each located in Barcelona, Spain.
On the initiative of UKROBORONPROM (UOP), Anthony Tether – former head of the Defense Advanced Research Projects Agency (DARPA) – was appointed as member of UOP Supervisory Board. This was reported by the press service of the SC”UkrOboronProm”.
Anthony Tether has been in charge of UKROBORONPROM long-term development for over a year and a half. He assists in implementing UOP development strategy, implementation of reforms, corporatization, and international audit. The former head of DARPA contributed to strengthening UKRBORONPROM’s export potential and investment development. Under his chairmanship, the State General Advanced Research and Development Agency (GARDA, the prototype of the American DARPA) was created.
“Almost two years ago, Anthony Tether strengthened our team and introduced American experience of long-term innovation development and management. He is a world-class specialist with international military and management experience. Together, we implemented many large-scale innovation projects and began to actively implement reforms. As a member of the Supervisory Board, Anthony Tether will help UKROBORONPROM to even more effectively implement the reform strategy and international audit,” said Roman Romanov, UKROBORONPROM Director General.
Earlier, Mykhaylo Zhurovs’kyy – the rector of the National Technical University of Ukraine “Kyiv Polytechnic Institute named after I. Sikorsky” – was elected as Chairman of the Supervisory Board. Lieutenant General Yaroslav Skal’ko, former commander-in-chief of the Ukrainian Air Force, was elected as Vice-Chairman.
On January 31, the UKROBORONPROM Supervisory Board – after a long-term meeting -took key decisions on the activities of the Concern. During the meeting, UOP management report was heard; strategic directions for UOP development, corporatization process of UOP enterprises-participants, the international audit, the system of effective anti-corruption measures, creation of an advisory body and other issues were discussed.
(Click for full article)
Summary: Comprehensive regenerative medicine policy framework to spur innovation, efficient access to potentially transformative products, while ensuring safety & efficacy.